Haleon (HLNCF) Depreciation & Amortization (CF) (2022 - 2023)
Haleon (HLNCF) recorded quarterly Depreciation & Amortization (CF) of $121.6 million in Q4 2023, up 26.46% on a QoQ basis from $96.2 million in Q4 2022, and up 26.46% year-over-year from $96.2 million in Q4 2022.
Haleon (HLNCF) Depreciation & Amortization (CF) (2022 - 2023) Analysis & Trends
Haleon has disclosed Depreciation & Amortization (CF) across 2 years of filings, most recently posting $121.6 million for Q4 2023.
- Quarterly Depreciation & Amortization (CF) rose 26.46% year-over-year to $121.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $121.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $77.8 million, changed 0.23% from the prior year.
- Depreciation & Amortization (CF) improved to $121.6 million in Q4 2023, from $96.2 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $121.6 million in Q4 2023 and troughed at $96.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Haleon | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 121.63 Mn |
| Dec 31, 2023 | 121.63 Mn |
| Dec 31, 2022 | 96.18 Mn |
| Dec 31, 2022 | 96.18 Mn |